Next Phase Newsletter

The corporate venture fund was founded in 2006 and is based in Boston, Massachusetts. The firm is looking to provide equity capital to seed and venture stage companies in the life science space, and invests across North America & Europe. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year.

The fund is currently looking for novel therapeutics, platform technologies, diagnostics, and vaccines. The fund is interested in novel drugs in broad disease areas including neuroscience (particularly neurodegeneration), immunology, inflammation, and rare disease, as well as diagnostics for neurodegenerative disorders. Current platform technology areas of interest include regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine.

The fund strongly prefers that the company has a strong management team with experience in the industry. The firm historically has only invested as a co-investor although they are capable and looking to take a lead position if the correct opportunity arises. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A private equity firm headquartered in Asia with multiple offices throughout USA and Asia has a dedicated life science investment team and invests in venture stage companies. The firm invests in various stages, typically start-up and early stage. For life science companies, the firm generally allocates USD 3-5 million per round. The firm is currently focused on opportunities in the US, Israel, and Asia.

The firm invests opportunistically in the life sciences. The firm seeks to invest in innovative therapeutics, diagnostics, and medical devices. For therapeutics, the firm generally invests in novel platform technologies and considers both small molecules and biologics. The firm is indication agnostic and will consider orphan diseases. The firm is also agnostic to the stage of development, but typically invests in companies with a lead asset in clinical trials. For medical devices, the firm is also opportunistic and generally invests in devices that are in the clinic. The firm generally only invests in new IP/NCEs, and does not invest in repurposed or reformulated products.

The firm is currently focused on private companies in the US, Israel and Asia. The firm generally requires a seat on the board of directors or observers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund part of a large holding company looks to provide a unique stepping stone for successful companies to broaden their global reach. The firm offers partners deep understanding of relevant audiences and a unique opportunity for truly innovative, trail-blazing consumer-related digital health ventures. The firm is looking to invest in digital therapeutics, POC diagnostics, and other dHealth companies from seed stage and beyond. The firm is interested in companies with well defined, relevant products and solutions, preferably with initial validation or proof-of-concept. The firm invests globally.

Within the digital health and POC diagnostics space, the firm has many areas of interest. These include, but are not limited to, telemedicine, remote monitoring, patient adherence, femtech and aging, medication dispensing, digital therapeutics, POC and home diagnostics.

The firm has no specific requirements for company and management team, and makes decisions on a case-by-case basis. The firm can lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An international corporation that manufactures and distributes printing, imaging and optics products develops and distributes medical imaging products for diagnostic use by healthcare professionals, including x-ray, ultrasonography, image analysis, and point-of-care diagnostics. The corporation has innovation centers are established in major regions around the world as the core engine of growth for the corporation. The mission is to gain a deeper understanding of customers’ needs and develop, through strategic partnerships and investments, novel products and solutions to expand the corporation’s business in existing and new markets.

The USA-based innovation arm focuses on healthcare, next generation enterprise solutions, workplace of the future, robotics, and connected intelligent enterprises (IoT, AI, Data Analytics). The firm typically makes Seed to Series A investments of less than $5 million with ownership stakes of less than 20% equity in private companies. The firm is looking to partner and/or invest in companies that can benefit from the variety of assets of the corporation (R&D, Manufacturing, distribution channel, field service) and are interested in building a large, sustainable business with the corporation.

The firm seeks to strengthen the corporation’s core business, explore new areas of innovation, and identify key players in these ecosystems. Within healthcare, the firm focuses on telemedicine and connected device solutions for applications such as patient management and virtual clinics. Other areas of interest include population health, patient engagement and medical image analysis. The firm considers products that have completed prototypes or achieved proof of concept with a clear path to FDA clearance (where needed).

The firm drives corporate innovation by managing the entire lifecycle of new business development, from ideation to actual business realization. The innovation centers closely collaborate with a diverse range of entities, such as academic institutes, research institutes, partner companies, and startups. The outcomes of collaboration become the co-innovations for our customers and ourselves. The firm would like to obtain distribution rights for companies located in their headquartered country; however, this is not a requirement for collaboration.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-headquartered firm is focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics globally for patients suffering from inflammatory and auto-immune diseases. To that end, the company has built a clinical late stage therapeutics pipeline and is seeking  collaborations with companies with compelling early-stage programs and technologies within its core therapeutic areas of interest, and is willing to consider multiple partnering structures ranging from investments (active or passive) to in-licensing. While primarily interested in therapeutics, assuming a fit with the firm’s areas of interest, the firm is willing to consider partnerships and investments around other technologies. Furthermore, the firm is willing to partner with companies across the globe.

The firm’s areas of interest are in inflammation and auto-immune conditions, with a focus on GI and dermatologic disease. Also of interest are any technologies relating to the microbiome. As a secondary interest, the firm will also consider therapeutics in the cardiovascular space.

Due to their flexibility as investors, the firm can assume varying roles in a partnership depending on the level of investment. When investing alongside other firms, the firm will not necessarily require exclusive rights to the assets. For larger investments, where the firm is supporting the majority of development activities, they generally will assume an involved role as a more pro-active partner with the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm founded in 2020 and is based in San Francisco, CA. The firm is expecting to close their first fund this year, targeting $100M. The firm is seeking to invest in Seed to Series A companies. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from Israel, Japan, Europe, Asia, etc.

Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies.

The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A Venture Capital firm based in San Francisco, CA, and has an additional office in Japan. The firm is investing from a new fund that closed in 2016. The firm generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 90% of its capital in the USA, Japan and Israel, with the remaining 10% open to global opportunities.

The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second-generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. The firm prefers to invest in technologies at an early stage of development.

The firm is interested in working with high quality management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.